AGIO — Agios Pharmaceuticals, Inc. stock price, charts and financials
QT51Agios Pharmaceuticals, Inc.Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
Latest market price
33.07
-0.54-1.61%
TA
Loading chart...
Snapshot
| Index | - | P/E | - | EPS (ttm) | -7.01 | Insider Own | 1.73% | Shs Outstand | 59.70M | Perf Week | -1.58% |
| Market Cap | 1.97B | Forward P/E | - | EPS next Y | -3.69 | Insider Trans | -6.65% | Shs Float | 55.89M | Perf Month | -5.84% |
| Enterprise Value | 1.91B | PEG | 0.03 | EPS next Q | -1.21 | Inst Own | - | Short Float | 13.48% | Perf Quarter | -3.19% |
| Income | -412.83M | P/S | 20.08 | EPS this Y | 18.97% | Inst Trans | - | Short Ratio | 6.59 | Perf Half Y | 18.45% |
| Sales | 98.34M | P/B | 1.92 | EPS next Y | 35.07% | ROA | -37.11% | Short Interest | 7.54M | Perf YTD | 21.49% |
| Book/sh | - | P/C | - | EPS next 5Y | - | ROE | -35.67% | 52W High | 46.00 -28.11% | Perf Year | -9.20% |
| Cash/sh | - | P/FCF | - | EPS past 3/5Y | - | ROIC | -43.30% | 52W Low | 22.24 48.70% | Perf 3Y | 21.38% |
| Dividend Est. | - | EV/EBITDA | - | Sales past 3/5Y | 56.83% - | Gross Margin | 87.92% | Volatility | 3.29% 3.69% | Perf 5Y | -26.80% |
| Dividend TTM | - | EV/Sales | 19.38 | EPS Y/Y TTM | -160.22% | Oper. Margin | -466.78% | ATR (14) | 1.36 | Perf 10Y | -29.13% |
| Dividend Ex-Date | - | Quick Ratio | 9.79 | Sales Y/Y TTM | 175.00% | Profit Margin | -418.24% | RSI (14) | 46.07 | Recom | 2.24 |
| Dividend Gr. 3/5Y | - | Current Ratio | 10.22 | EPS Q/Q | 12.44% | SMA20 | -1.36% | Beta | 0.63 | Target Price | 42.67 |
| Payout | 0.00% | Debt/Eq | 0.03 | Sales Q/Q | 275.00% | SMA50 | -4.35% | Rel Volume | 1.43 | Prev Close | 33.61 |
| Employees | 540 | LT Debt/Eq | 0.02 | Earnings | Oct 29 | SMA200 | 7.67% | Avg Volume | 1.09M | Price | 33.07 |
| IPO Date | Jul 24, 2013 | Option/Short | Yes / Yes | EPS/Sales Surpr. | -2.13% 69.52% | Net Debt/EBITDA | 0.16 | Volume | 1,565,926 | Change | -1.61% |
Analyst Ratings
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Jul-30-26 | Reiterated | HC Wainwright & Co. | Buy | $52 → $55 |
| Jul-21-26 | Reiterated | HC Wainwright & Co. | Buy | $54 → $52 |
| Jul-07-26 | Reiterated | RBC Capital | Sector Perform | $53 → $32 |
| Jul-07-26 | Reiterated | Truist Securities | Buy | $36 → $41 |
| Jun-15-26 | Reiterated | HC Wainwright & Co. | Buy | $50 → $54 |
| Apr-30-26 | Reiterated | Truist Securities | Buy | $39 → $36 |
| Apr-20-26 | Reiterated | HC Wainwright & Co. | Buy | $62 → $50 |
| Feb-12-26 | Reiterated | Truist Financial | Buy | $38 → $39 |
| Dec-26-25 | Reiterated | Leerink Partners | Outperform | $34 → $40 |
| Dec-24-25 | Reiterated | Truist Securities | Buy | $32 → $38 |
Latest News· Times ET
Sep-10-26
Sep-10-2604:02AM
Sep-04-26
Sep-04-2611:30AM
Sep-03-26
Sep-03-2611:26PM
Aug-20-26
Aug-20-2605:07AM
Aug-13-26
Aug-13-2606:00AM
Aug-12-26
Aug-12-2611:31PM
Aug-11-26
Aug-11-2612:58PM
Aug-07-26
Aug-07-2607:36AM
Aug-04-26
Aug-04-2601:07PM
Aug-03-26
Aug-03-2612:16AM
Jul-31-26
Jul-31-2611:36AM
Jul-30-26
Jul-30-2611:34AM
09:53AM
06:06AM
Agios Pharmaceuticals Q2 Earnings Call Highlightsmarketbeat.com
Company
Agios Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to the research and advancement of new treatments, specifically targeting cellular metabolism and related biological fields. The company's offerings include PYRUKYND (mitapivat), a medication designed to activate both wild-type and various mutated pyruvate kinase (PK) enzymes, used in the management of hemolytic anemias. Additionally, Agios is developing AG-946, which is currently undergoing Phase I clinical studies for treating hemolytic anemias and other diseases. Established in 2007, the company's main office is located in Cambridge, Massachusetts.
Ownership
Per-holder 13F data hasn't been ingested for this ticker yet.
Financial Statements
DataTimeframe
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 99 | 54 | 36 | — | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 12 | 12 | 4 | — | — | — | — | — | — | |
| Gross Profit | 87 | 43 | 32 | — | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 193 | 180 | 157 | — | — | — | — | — | — | |
| Research and Development | 353 | 334 | 301 | — | — | — | — | — | — | |
| Other Operating Expense | -1 | 1 | 0 | — | — | — | — | — | — | |
| Operating Income | -460 | -472 | -426 | — | — | — | — | — | — | |
| Interest Expense | 0 | 0 | 0 | — | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 47 | 58 | 1,144 | — | — | — | — | — | — | |
| Net Income Before Taxes | -412 | -414 | 718 | — | — | — | — | — | — | |
| Income Taxes | -1 | -1 | 44 | — | — | — | — | — | — | |
| Consolidated Net Income | -411 | -413 | 674 | — | — | — | — | — | — | |
| Net Income From Continuing Operations | -411 | -413 | 674 | — | — | — | — | — | — | |
| Net Income | -411 | -413 | 674 | — | — | — | — | — | — | |
| EPS (Recurring) | -7.01 | -7.12 | 11.86 | — | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -7.01 | -7.12 | 11.86 | — | — | — | — | — | — | |
| EPS (Diluted) | -7.01 | -7.12 | 11.64 | — | — | — | — | — | — | |
| EBITDA | -417 | -409 | 724 | — | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | 2.82 | — | — | — | — | — | — | |
| Price To Sales Ratio | 19.71 | 29.24 | 52.03 | — | — | — | — | — | — | |
| Gross Margin | 87.88 | 79.63 | 88.89 | — | — | — | — | — | — | |
| Operating Margin | -464.65 | -874.07 | -1,183.33 | — | — | — | — | — | — | |
| Net Margin | -415.15 | -764.81 | 1,872.22 | — | — | — | — | — | — | |
| Shares Outstanding | 59 | 58 | 57 | — | — | — | — | — | — | |
| Market Capitalization | 1,951 | 1,579 | 1,873 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
Insider Trading
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Gheuens Sarah | Chief Medical Officer | Aug 04 '26 | Sale | 30.48 | 30,000 | 914,400 | 54,645 | Aug 06 |
| Backstrom Jay T. | Director | Jul 08 '26 | Option Exercise | 0.00 | 1,447 | 0 | 2,894 | Jul 10 |
| Gheuens Sarah | Chief Medical Officer | Jul 01 '26 | Option Exercise | 0.00 | 8,375 | 0 | 88,652 | Jul 02 |
| Gheuens Sarah | Chief Medical Officer | Jul 01 '26 | Sale | 37.56 | 4,007 | 150,503 | 84,645 | Jul 02 |
| Ballal Rahul D. | Director | Jun 18 '26 | Option Exercise | 0.00 | 2,816 | 0 | 15,230 | Jun 23 |
| CAPELLO JEFFREY D | Director | Jun 18 '26 | Option Exercise | 0.00 | 2,816 | 0 | 10,865 | Jun 23 |
| Foster-Cheek Kaye I | Director | Jun 18 '26 | Option Exercise | 0.00 | 2,816 | 0 | 10,284 | Jun 23 |
| FOUSE JACQUALYN A | Director | Jun 18 '26 | Option Exercise | 0.00 | 2,816 | 0 | 154,156 | Jun 23 |
| Ho Maykin | Director | Jun 18 '26 | Option Exercise | 0.00 | 2,816 | 0 | 19,848 | Jun 23 |
| Owen Adams Catherine | Director | Jun 18 '26 | Option Exercise | 0.00 | 2,816 | 0 | 10,865 | Jun 23 |
| Scadden David | Director | Jun 18 '26 | Option Exercise | 0.00 | 2,816 | 0 | 20,419 | Jun 23 |
| Smith Cynthia | Director | Jun 18 '26 | Option Exercise | 0.00 | 2,816 | 0 | 15,230 | Jun 23 |
| Viswanadhan Krishnan | Chief Strategy and Operations | Jun 18 '26 | Option Exercise | 0.00 | 3,000 | 0 | 9,000 | Jun 23 |
| Goff Brian | Chief Executive Officer | Jun 18 '26 | Option Exercise | 0.00 | 39,000 | 0 | 39,000 | Jun 23 |
| Burns James William | Chief Legal Officer | Jun 18 '26 | Option Exercise | 0.00 | 3,000 | 0 | 9,000 | Jun 23 |
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.